Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,130 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 0.9 Normal Saline Clear all

Conditions: Geographic Atrophy, Age Related Macular Degeneration
Interventions: IONIS-FB-Lrx, Placebo (sterline saline 0.9%); Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 55 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 24
States / cities: Phoenix, Arizona • Beverly Hills, California • Encino, California + 20 more

Conditions: Sialorrhea
Interventions: Atropine (0.01mg/kg), Glycopyrrolate (0.01mg/kg), Normal saline 0.9%; Drug
Lead sponsor: Craig J. Huang; Other
Eligibility: 6 Months to 18 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Ureteral Stent Placement, Kidney Stone
Interventions: Ketorolac Trometamol 30Mg/1mL Injection, Normal saline; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Shock, Septic
Interventions: Lactated Ringer, Normal Saline, Plasma-lyte; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Months to 17 Years
Enrollment: 9,041 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 22
States / cities: Davis, California • Los Angeles, California • San Francisco, California + 19 more

Conditions: Obesity and Obesity-related Medical Conditions
Interventions: MET233 and MET097, Placebo, MET097; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 201 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cypress, California

Conditions: Breast Cancer, Breast Neoplasm
Interventions: Docetaxel - Dose A, Anastrozole, cyclophosphamide, Docetaxel - Dose B, Doxorubicin hydrochloride, Tamoxifen Citrate, Capecitabine - Dose B, Capecitabine - Dose A; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Mucositis, Multiple Myeloma
Interventions: 0.9% Sodium Chloride irrigation solution, Cryotherapy (ice chips), Calcium phosphate (Caphosol) Ca2+/PO43- mouth rinse; Drug · Other · Device
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pain, Postoperative
Interventions: Intercostal Nerve Cryoablation, Bupivacaine liposomal injectable suspension, Patient-controlled analgesia (PCA); Device · Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pain, Healthy Volunteers
Interventions: Naproxen (BAYH006689), Placebo Gel, A solution of 0.9% Saline; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Clostridoides Difficile Associated Disease
Interventions: C.difficile vaccine, Saline Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years and older
Enrollment: 32,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 142
States / cities: Athens, Alabama • Guntersville, Alabama • Huntsville, Alabama + 90 more

Conditions: Respiratory Syncytial Virus, Human Metapneumovirus
Interventions: mRNA-1345, mRNA-1365, Placebo, Nimenrix; Biological · Drug
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 5 Months to 24 Months
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 12
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Melrose Park, Illinois + 8 more

Conditions: Hysterectomy, Blood Loss, Surgical
Interventions: Tranexamic Acid, Sodium Chloride; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Traumatic Brain Injury
Interventions: autologous bone marrow mononuclear cells, Placebo Infusion; Biological · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 5 Years to 17 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 2
States / cities: Phoenix, Arizona • Houston, Texas

Conditions: Triple Negative Breast Cancer
Interventions: Trilaciclib, Sacituzumab Govitecan-hziy; Drug
Lead sponsor: G1 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 22
States / cities: Chandler, Arizona • Bakersfield, California • Los Angeles, California + 18 more

Conditions: Pain Management
Interventions: Bupivacaine/Epinephrine, Saline; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Esophageal Spasm
Interventions: Magnesium sulfate, Normal Saline; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: PRM-151, Placebo; Biological · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Boston, Massachusetts • Durham, North Carolina

Conditions: Leukemia
Interventions: Clofarabine; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atrial Flutter With Rapid Ventricular Response
Interventions: Magnesium Sulfate 2g, Magnesium Sulfate 4g, Saline (0.9% NaCl); Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Oak Lawn, Illinois

Conditions: Clostridium Difficile Infection
Interventions: SER-109, Placebo; Biological · Drug
Lead sponsor: Seres Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 51
States / cities: North Little Rock, Arkansas • Mather, California • Mountain View, California + 46 more

Conditions: Fluid Loss, Symptom Complex, Triple, Emergencies
Interventions: Lactated Ringer Solution, Normal Saline 0.9% Infusion Solution Bag; Drug
Lead sponsor: Nicholas M Mohr; Other
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Bacterial Infections
Interventions: KSP-1007, Placebo:0.9% sodium chloride, Meropenem; Drug · Other
Lead sponsor: Sumitovant Biopharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Severe Osteoarthritis of the Knee
Interventions: Ampion, Saline; Biological · Drug
Lead sponsor: Ampio Pharmaceuticals. Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 1,043 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Cutaneous T-cell Lymphoma
Interventions: Vitamin B12, Folic Acid, Pralatrexate; Dietary Supplement · Drug
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 10
States / cities: Duarte, California • Redwood City, California • New Haven, Connecticut + 6 more

Search by objective public record fields.

Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation

NSAIDs Stent Study

Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis

A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes

Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer

Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation

Intercostal Nerve Cryoablation for Postoperative Pain Management

A Study to Learn About Whether BAY H006689 Causes an Allergic Reaction When Applied as a Topical Gel in Healthy Participants

A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

IV Tranexamic Acid Prior to Hysterectomy

Pediatric Autologous Bone Marrow Mononuclear Cells for Severe Traumatic Brain Injury

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Local Anesthesia for Facial Fractures

Magnesium for Peroral Endoscopic Myotomy

A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Clofarabine Bone Marrow Cytoreduction

MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation

ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection

Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation

Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects

Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee.

Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma